title: Alfimeprase to succeed Genentech's alteplase?
authors.forename: Brian
authors.initials: B
authors.lastname: Vastag
mesh_terms: D001777:Blood Coagulation; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008666:Metalloendopeptidases / Q000191:economics* / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy* / Q000191:economics*; D010959:Tissue Plasminogen Activator / Q000191:economics* / Q000627:therapeutic use*; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D008666:Metalloendopeptidases; C436755:alfimeprase